Minocycline and matrix metalloproteinase inhibition in acute intracerebral hemorrhage: a pilot study
European Journal of Neurology2017Vol. 24(11), pp. 1384–1391
Citations Over TimeTop 10% of 2017 papers
Jason J. Chang, May Kim‐Tenser, Benjamin Emanuel, G. Morgan Jones, Kristina Chapple, Ahmad Alikhani, Nerses Sanossian, William J. Mack, Georgios Tsivgoulis, Andrei V. Alexandrov, Tayebeh Pourmotabbed
Abstract
High-dose intravenous minocycline can be safely administered to patients with ICH. Larger randomized clinical trials evaluating the efficacy of minocycline and MMP-9 inhibition in ICH patients are required.
Related Papers
- → Association of baseline hematoma and edema volumes with one-year outcome and long-term survival after spontaneous intracerebral hemorrhage: A community-based inception cohort study(2020)13 cited
- → The use of serum glial fibrillary acidic protein test as a promising tool for intracerebral hemorrhage diagnosis in Chinese patients and prediction of the short-term functional outcomes(2015)34 cited
- → Serum β2-microglobulin is closely associated with 3-month outcome of acute intracerebral hemorrhage: a retrospective cohort study(2022)1 cited
- → Morbilidad de la hemorragia intracerebral(1998)9 cited
- → Malondialdehyde levels and clinical outcomes assessed by the modified Rankin scale in patients with acute intracerebral hemorrhagic stroke(2021)